Clinical Trial · NCT04459273

PET Biodistribution Study of 68Ga-FAPI-46 in Patients With Different Malignancies: An Exploratory Biodistribution Study With Histopathology Validation

Overview

This exploratory study investigates how an imaging technique called 68Ga-FAPi-46 PET/CT can determine where and to which degree the FAPI tracer (68Ga-FAPi-46) accumulates in normal and cancer tissues in patients with cancer. Because some cancers take up 68Ga-FAPi-46 it can be seen with PET. FAP stands for Fibroblast Activation Protein. FAP is produced by cells that surround tumors (cancer associated fibroblasts). The function of FAP is not well understood but imaging studies have shown that FAP can be detected with FAPI PET/CT. Imaging FAP with FAPI PET/CT may in the future provide additional information about various cancers.

Sponsor

Jonsson Comprehensive Cancer Center (UCLA)

Phase

Phase 1

Contacts

Stephanie Lira (Clinical Trials Program Manager)

stephanielira@mednet.ucla.edu

(310) 206-7372

Hamzah Alam (Clinical Research Coordinator)

halam@mednet.ucla.edu

3102067372

Maria Contreras (Clinical Research Coordinator)

mmcontreras@mednet.ucla.edu

3108257336

ClinicalTrials.gov

NCT04459273

Drug / Compound

68Ga-FAPi-46

Isotope(s):

Target(s):

Ligand Class: Small Molecules

Chelator: DOTA

Eligibility

Inclusion

Patients are ≥ 18 years old at the time of the radiotracer administration.
Patients who are scheduled to undergo surgical resection or tissue biopsy of the primary tumor and/or metastasis
Patient can provide written informed consent
Patient is able to remain still for duration of imaging procedure (up to one hour)

Exclusion

Patient is pregnant or nursing
Patients with any new cancer therapy between the baseline PET/CT and the investigational FAPI PET/CT
Patient has underlying disease which might interfere with the collection of high quality data

Patient Education

Patient education not yet provided.

Publications

Publications not yet provided.

Locations

Loading…